May 13th 2024
Tiffany Bostwick, P.A., discussed the importance of communication and education around adverse effects for both oncology nurses and for patients with advanced endometrial cancer who are treated with immunotherapies.
Conversations with Patients With Advanced Endometrial Cancer Before and After Diagnosis
November 29th 2022Nurse Practitioners Kathleen Lutz and Kimberly Halla describe the conversations they have with patients with advanced endometrial cancer before and after diagnosis and the common questions they hear.
Initial Consultation of Patients With Advanced Endometrial Cancer
Kimberly Halla, NP, explains the staging of endometrial cancer and the standards for biomarker testing at her institution.
Symptoms and Diagnosis of Endometrial Cancer
Kimberly A. Spickes, CNP, gives an overview of the typical symptoms women with endometrial cancer present with, discusses how these symptoms are similar and different from those seen with other gynecologic malignancies, and reviews risk factors for endometrial cancer.
FDA Follow-Up: Utilizing Pembrolizumab for MSI-H/dMMR Advanced Endometrial Carcinoma
April 8th 2022Courtney Arn, APRN-CNP, a nurse practitioner who supported cohorts D and K of the KEYNOTE-158 study, discusses the recent approval of pembrolizumab for patients with MSI-H/dMMR advanced endometrial carcinoma.
Maintenance Selinexor Yields Survival Benefit in Advanced or Recurrent Endometrial Cancer
March 23rd 2022Selinexor demonstrated impressive efficacy in extending progression-free survival among patient with advanced or recurrent endometrial cancer, particularly among patients with wild-type p53 endometrial cancer.
Lenvatinib/Pembrolizumab Combo Continues to Show Benefit in Advanced Endometrial Cancer
November 21st 2021A presentation at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting shared updated findings on the efficacy of lenvatinib plus pembrolizumab in patients with advanced endometrial cancer.
Study Results Advise Against Avelumab Maintenance Therapy in Endometrial Cancer Treatment
September 8th 2021After the 3-arm, JAVELIN Ovarian 100 trial terminated at the interim analysis, researchers concluded that avelumab is not yet a suitable first-line treatment option for patients with advanced epithelial cancer.
FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Recurrent/Advanced Solid Tumors
August 17th 2021The regulatory decision is based on findings from collective data from the dMMR endometrial cancer cohort A1 and the dMMR solid-tumor, non-endometrial cancer, cohort F of the ongoing phase 1 GARNET trial (NCT02715284).
FDA Approves Dostarlimab for dMMR Advanced Endometrial Cancer
April 22nd 2021The FDA approved dostarlimab (Jemperli) for the treatment of patients with recurrent or advanced endometrial cancer that progressed on or after platinum-containing chemotherapy and whose cancer is DNA mismatch repair deficient (dMMR), as determined by an FDA-approved test.
IMRT Betters Patient-Reported Outcomes in Cervical, Endometrial Cancer
May 5th 2020A reduction in patient-reported symptomatic adverse events (AEs) was observed with intensity-modulated radiotherapy (IMRT) compared with standard radiotherapy in patients with cervical or endometrial cancer, whereas no difference was observed with regard to clinician-reported AE.
FDA Grants Breakthrough Therapy Designation to Drug Duo for Endometrial Cancer
August 2nd 2018The FDA has granted a second breakthrough therapy designation to the combination use of lenvatinib (Lenvima) and pembrolizumab (Keytruda) for the treatment of patients with advanced and/or metastatic non–microsatellite instability high (MSI-H)/proficient mismatch repair endometrial carcinoma who have progressed after ≥1 prior systemic therapy.
Geography, Race, and Genetic Variation in Endometrial Cancer
February 21st 2018A study done at SUNY Downstate Hospital found that black women of Caribbean descent with type I or type II endometrial cancer expressed significant differences in genetic variations when compared with a nationwide population of patients with endometrial cancer.